WO1999035255A3 - Compositions and methods for regulated secretion from neuroendocrine cell lines - Google Patents

Compositions and methods for regulated secretion from neuroendocrine cell lines Download PDF

Info

Publication number
WO1999035255A3
WO1999035255A3 PCT/US1999/000631 US9900631W WO9935255A3 WO 1999035255 A3 WO1999035255 A3 WO 1999035255A3 US 9900631 W US9900631 W US 9900631W WO 9935255 A3 WO9935255 A3 WO 9935255A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
cells
cell lines
present
Prior art date
Application number
PCT/US1999/000631
Other languages
French (fr)
Other versions
WO1999035255A9 (en
WO1999035255A8 (en
WO1999035255A2 (en
Inventor
Samuel A Clark
Anice E Thigpen
Original Assignee
Betagene Inc
Samuel A Clark
Anice E Thigpen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagene Inc, Samuel A Clark, Anice E Thigpen filed Critical Betagene Inc
Priority to AU24551/99A priority Critical patent/AU2455199A/en
Priority to EP99904073A priority patent/EP1045898A2/en
Priority to CA 2318376 priority patent/CA2318376A1/en
Publication of WO1999035255A2 publication Critical patent/WO1999035255A2/en
Publication of WO1999035255A8 publication Critical patent/WO1999035255A8/en
Publication of WO1999035255A3 publication Critical patent/WO1999035255A3/en
Publication of WO1999035255A9 publication Critical patent/WO1999035255A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/74—Alginate

Abstract

The present invention provides compositions and methods of comprising engineered human neuroendocrine cell lines having a regulated secretory pathway. More particularly, the present invention provdes methods and compositions for engineering regulated secretion into cells. Certain aspects of the invention provide glycemic sensing mechanisms to a population of genetically engineered cells. In particular embodiments, the present invention provides compositions and methods of providing indirect glycemic sensing mechanisms to a population of genetically engineered cells. Specifically contemplated are methods and compositions for engineering indirect glucose sensing and glucose counter regulation capacity into cells. Methods of using these cells for minimizing hypoglycemia in diabetic therapy are also disclosed.
PCT/US1999/000631 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines WO1999035255A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU24551/99A AU2455199A (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines
EP99904073A EP1045898A2 (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines
CA 2318376 CA2318376A1 (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US7119398P 1998-01-12 1998-01-12
US7120998P 1998-01-12 1998-01-12
US7255698P 1998-01-12 1998-01-12
US60/071,193 1998-01-12
US60/072,556 1998-01-12
US60/071,209 1998-01-12
US8784898P 1998-06-03 1998-06-03
US8782198P 1998-06-03 1998-06-03
US60/087,821 1998-06-03
US60/087,848 1998-06-03

Publications (4)

Publication Number Publication Date
WO1999035255A2 WO1999035255A2 (en) 1999-07-15
WO1999035255A8 WO1999035255A8 (en) 1999-09-10
WO1999035255A3 true WO1999035255A3 (en) 1999-10-28
WO1999035255A9 WO1999035255A9 (en) 2001-05-31

Family

ID=27535873

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/000633 WO1999035242A1 (en) 1998-01-12 1999-01-11 Media for neuroendocrine cells
PCT/US1999/000551 WO1999035495A2 (en) 1998-01-12 1999-01-11 Identification of substances that modify cellular secretory function
PCT/US1999/000631 WO1999035255A2 (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US1999/000633 WO1999035242A1 (en) 1998-01-12 1999-01-11 Media for neuroendocrine cells
PCT/US1999/000551 WO1999035495A2 (en) 1998-01-12 1999-01-11 Identification of substances that modify cellular secretory function

Country Status (4)

Country Link
EP (2) EP1045898A2 (en)
AU (3) AU2113199A (en)
CA (2) CA2318379A1 (en)
WO (3) WO1999035242A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2281764C2 (en) * 2000-03-17 2006-08-20 Адзиномото Ко., Инк. Medicinal agents for treatment of complications associated with diabetes mellitus and neuropathy and their using
US7501231B2 (en) 2001-03-23 2009-03-10 University Of Ottawa Methods and compositions for cryopreservation of dissociated primary animal cells
US7166463B2 (en) 2001-11-16 2007-01-23 The Regents Of The University Of Colorado Nucleic acids encoding modified olfactory cyclic nucleotide gated ion channels
WO2006133506A1 (en) 2005-06-17 2006-12-21 Vital Health Sciences Pty Ltd A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
ATE448247T1 (en) 2005-09-22 2009-11-15 Biocompatibles Uk Ltd FUSION POLYPEPTIDES FROM GLP-1 (GLUCAGON-LIKE PEPTIDE-1) WITH INCREASED PEPTIDE RESISTANCE
CN101360820A (en) 2006-01-04 2009-02-04 巴克斯特国际公司 Oligopeptide-free cell culture media
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
EP2495307B9 (en) 2006-07-13 2018-05-02 Wyeth LLC Production of coagulation factor IX with improved glycosylation pattern
JP2010525818A (en) 2007-05-01 2010-07-29 ヴィトロライフ スウェーデン アクチボラゲット Culture medium for developing cells with increased lipoic acid concentration
RU2010114039A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) USE OF OCTREOTIDE AS A THERAPEUTIC
EP2163243A1 (en) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
EP3431588A1 (en) * 2009-08-11 2019-01-23 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
AU2011213484B2 (en) * 2010-02-05 2015-07-09 Phosphagenics Limited Carrier composition
EP2531047A4 (en) 2010-02-05 2014-03-19 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
CN102821791B (en) 2010-03-30 2015-06-17 磷肌酸有限公司 Transdermal delivery patch
EP2678415B1 (en) * 2011-02-22 2019-06-19 Promethera Biosciences SA Fill system for providing uniform concentrations and volumes and methods thereof
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US8945876B2 (en) 2011-11-23 2015-02-03 University Of Hawaii Auto-processing domains for polypeptide expression
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
WO2015066631A2 (en) * 2013-11-01 2015-05-07 University Of Notre Dame Du Lac Cell culture medium and bioprocess optimization
ES2716674T3 (en) 2013-11-22 2019-06-14 Centre Nat Rech Scient Frozen cell ready for testing and method to minimize variability in the performance of the same
US10918110B2 (en) 2015-07-08 2021-02-16 Corning Incorporated Antimicrobial phase-separating glass and glass ceramic articles and laminates
TW202330904A (en) * 2015-08-04 2023-08-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
CN108601732A (en) 2015-12-09 2018-09-28 磷肌酸有限公司 pharmaceutical preparation
KR102647670B1 (en) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 method
KR102569522B1 (en) * 2017-11-24 2023-08-24 주식회사 차바이오랩 Composition for cryopreservation of cell and method for cryopreservation of cell using the same
US20230091910A1 (en) * 2019-04-02 2023-03-23 Centagen, Inc. Engineered System of Stem Cell Rejuvenation to Treat Aging and Disease
CN114868736B (en) * 2022-03-08 2022-12-09 四川中科奥格生物科技有限公司 Islet cell stabilizing solution and preparation method and application thereof
CN114561337B (en) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 Monoclonal enhancement culture medium and method for improving clone formation rate of HepG2 cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026321A2 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180662A (en) * 1988-01-05 1993-01-19 The United States Of America As Represented By The Department Of Health And Human Services Cytotoxic T lymphocyte activation assay
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
EP0550760A1 (en) * 1991-07-18 1993-07-14 Fuji Yakuhin Kogyo Kabushiki Kaisha Serum-free tissue culture medium containing tissue inhibitor of metalloproteinase and method for cell growth
GB9125052D0 (en) * 1991-11-26 1992-01-22 Isis Innovation Culture of bone cells
FR2726005B1 (en) * 1994-10-10 1997-01-03 Adim IMMORTALIZED LINES OF CEREBRAL ENDOTHELIAL CELLS AND THEIR APPLICATIONS FOR THE TREATMENT OF DIFFERENT NEUROLOGICAL OR PSYCHIATRIC PRIMARY AND SECONDARY DISORDERS OR DISEASES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026321A2 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLARK S A ET AL: "Novel insulinoma cell lines produced by iterative engineering of GLUT2, glucokinase, and human insulin expression [published erratum appears in Diabetes 1997 Oct;46(10):1663].", DIABETES, (1997 JUN) 46 (6) 958-67., XP002112279 *
HOHMEIER H E ET AL: "Regulation of insulin secretion from novel engineered insulinoma cell lines.", DIABETES, (1997 JUN) 46 (6) 968-77., XP002112280 *

Also Published As

Publication number Publication date
AU2112199A (en) 1999-07-26
WO1999035495A2 (en) 1999-07-15
WO1999035255A9 (en) 2001-05-31
EP1045898A2 (en) 2000-10-25
WO1999035255A8 (en) 1999-09-10
WO1999035242A1 (en) 1999-07-15
EP1047938A2 (en) 2000-11-02
CA2318379A1 (en) 1999-07-15
WO1999035242A9 (en) 1999-09-30
WO1999035255A2 (en) 1999-07-15
AU2113199A (en) 1999-07-26
WO1999035495A3 (en) 1999-11-25
CA2318376A1 (en) 1999-07-15
AU2455199A (en) 1999-07-26

Similar Documents

Publication Publication Date Title
WO1999035255A3 (en) Compositions and methods for regulated secretion from neuroendocrine cell lines
WO2004021858A3 (en) Blood glucose level control
WO2000047219A3 (en) Methods and reagents for treating glucose metabolic disorders
PL346520A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
WO2002018936A3 (en) Methods of monitoring glucose levels in a subject and uses thereof
MXPA05007470A (en) Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes.
EP0832203A4 (en) Use of neuro-derived fetal cell lines for transplantation therapy
AU7432796A (en) Retrievable bioartificial implants
DE69723230D1 (en) IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL)
AU2003269820A8 (en) Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods
MY135783A (en) Nutritional composition for controlling blood sugar level
LT2002063A (en) Low-dose metformin and gliburide combinations for treating diabetes
WO2002015920A3 (en) Treatment of hyperproliferative diseases
WO2004074451A3 (en) Loading of cells with antigens by electroporation
WO2002012328A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000057921A3 (en) Peroral gene therapy of diabetes and obesity
NO975545L (en) Cell line that produces analgesic compounds for the treatment of pain
WO2005117576A3 (en) Modification of sugar metabolic process in transgenic cells, tissues and animals
AU1720697A (en) Nutrient composition for exercise
AU2003251975A1 (en) Selected cell delivery for heart failure
AU1476901A (en) Methods for regulating blood glucose and appetite suppression in type 2 diabetics
WO2000066158A3 (en) Use of cytokines and mitogens to inhibit pathological immune responses
ZA200200340B (en) Storage of microorganisms, cells and tissue.
WO2004044127A3 (en) Stem cell populations
AU2003288793A1 (en) Pharmaceutical compound containing silymarin and carbopol®, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 28/99 UNDER (63) REPLACE "60/971209 (CIP)" BY "60/071209 (CIP)"

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2318376

Country of ref document: CA

Ref country code: CA

Ref document number: 2318376

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999904073

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200005200

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1999904073

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/59-59/59, DRAWINGS, REPLACED BY NEW PAGES 1/58-58/58; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999904073

Country of ref document: EP